La cadena de opciones muestra datos clave de las opciones de acciones de Windtree Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Windtree Therapeutics..

Windtree Therapeutics (NASDAQ:WINT) Bolsa, Cadena de Opciones

Windtree Therapeutics

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics Inc

Windtree Therapeutics Inc arrants (25/03/2026)

WINTO GROUP HLDGS LTD by WINTO GROUP HLDGS LTD.

Wintrust Financial Corporation - Common Stock

Wintrust Financial Corp

Wintrust Financial Corporation - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series D

Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E

Macro Economic Events

News

Economics

China's President Xi Meets British Prime Minister Starmer In Rio, Calls For Strengthening Strategic Partnership, Cooperation In Trade, Clean Energy, And AI Governance; Highlights Mutual Respect And Deeper Political Trust To Tackle Global Challenges

EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.35) by 91.43 percent. This is a 59.88 percent increase over losses of $(1.67) per share from the same period last year. The company reported quarterly sales of $7.36 million which beat the analyst consensus estimate of $5.20 million by 41.62 percent. This is a 53.12 percent decrease over sales of $15.71 million the same period last year.

Earnings

EONR

EON Resources Q3 EPS $(0.67) Misses $(0.35) Estimate, Sales $7.36M Beat $5.20M Estimate

With the conversion unit already shipped and located on site, Eco Wave Power plans to complete installation by the end of Q1 2025.

Contracts

WAVE

Eco Wave Power Receives Final Permit From U.S. Army Corps Of Engineers For U.S. First Wave Energy Project

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will release earnings results for the third quarter, before the <a href="https://www.benzinga.com/quote/WMT/earnings">opening bell on Nov. 19</a>.
Analysts expect the Bentonville, Arkansas-based company to report quarterly earnings at 53 cents per share. That&#8217;s up from 51 cents per share in the year-ago period. Walmart projects to report quarterly revenue of $166.57 billion, compared to $159.44 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Friday, Jefferies analyst Corey Tarlowe maintained Walmart with a Buy rating and raised the price target from $90 to $100.
With the recent buzz around Walmart, some investors may be eyeing potential gains from the company's dividends, too. Walmart currently offers an annual dividend yield of 0.99%, which is a quarterly dividend amount of 20.75 cents per share (83 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $609,043 or around 7,229 shares. For a more modest $100 per month or $1,200 per year, you would need $121,826 or around 1,446 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend (83 cents). So, $6,000 / $0.83 = 7,229 ($500 per month), and $1,200 / $0.83 = 1,446 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
WMT Price Action: Shares of Walmart fell 0.3% to close at $84.25 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Image via Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Walmart Stock Ahead Of Q3 Earnings

Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) announced today a collaboration with bp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>, LSE: BP.L))) on the companies' shared intent to form a crop-based biofuel feedstock joint venture (JV).
The JV envisaged by Corteva and bp would produce and deliver crop-based biofuel feedstocks to help meet the anticipated growth in demand for 'sustainable aviation fuel' (SAF).
A number of countries around the world have, or are in the process of implementing, mandates or tax incentives to promote the decarbonization of the aviation sector. In the EU a SAF mandate begins in 2025 that will require fuel uplift at EU airports to contain at least 20% SAF by 2035 and 70% by 2050.
To help meet this demand, Corteva and bp have executed a non-binding memorandum of understanding, with the intent of forming a JV that would aim to progressively scale up volume, reaching delivery&nbsp;of one million metric tons per year of biofuel feedstocks for SAF production by the mid-2030s.
Corteva plans to contract with farmers in North and South America, and Europe, to grow proprietary Corteva mustard seed, sunflower and canola feedstocks well-suited for SAF production. These crops are integral to large scale agriculture around the world. The JV would aim to introduce new cropping systems to produce oil that meets EU RED III criteria, and qualifies for US Low Carbon Intensity policy incentives, while creating a new revenue stream for farmers.

Biotech

General

CTVA

Corteva Announces A Collaboration With bp On The Companies' Shared Intent To Form A Crop-Based Biofuel Feedstock Joint Venture; The JV Envisaged By Corteva And bp Would Produce And Deliver Crop-Based Biofuel Feedstocks To Help Meet The Anticipated Growth In Demand For 'Sustainable Aviation Fuel'

Morgan Stanley analyst Tejas Savant maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight and lowers the price target from $32 to $21.

Price Target

Analyst Ratings

MYGN

Morgan Stanley Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $21

WIIM

XCUR

Exicure shares are trading higher after the company reported a year-over-year increase in Q3 PES results. Additionally, the company announced it entered into a purchase agreement for $1.3 million and $8.7 million in equity financing.

Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model
New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published historical rates
Annamycin demonstrates an even greater potential than previously reported to address a significant AML patient population for which treatment options are extremely limited
New data from MB-106 trial show median overall survival of 11.6 months in subjects receiving AnnAraC as 2nd line therapy
HOUSTON, Nov. 18, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in acute myeloid leukemia ("AML").&nbsp; This includes data from preclinical in vitro studies recently accepted for online publication at the upcoming American Society of Hematology ("ASH") Annual Meeting, and correlates with efficacy demonstrated by recent preliminary clinical data in subjects who were relapsed from or refractory to first line Venetoclax regimens and were then treated with Annamycin in combination with Ara-C ("AnnAraC").

MBRX

Moleculin Biotech  Announces New Findings Supporting The Ability Of Annamycin To Overcome Resistance To Venetoclax In Acute Myeloid Leukemia; Preclinical Data Accepted For Online Publication At ASH Annual Meeting Reveal Significant Activity Of Annamycin In Venetoclax Resistant AML Model

Morgan Stanley analyst Hamza Fodderwala maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $325 to $355.

CRWD

Morgan Stanley Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $355

THAR

Tharimmune shares are trading higher after the company announced it will present at the 75th AASLD liver meeting.

ANIX

Anixa Biosciences Initiates Dosing In The Third Cohort Of Its Ovarian Cancer CAR-T Clinical Trial

Coinbase CEO Brian Armstrong has proposed <a href="https://www.benzinga.com/money/what-is-income-tax">eliminating individual income taxes </a>in the U.S., suggesting a radical shift in the tax burden to businesses and alternative revenue sources like sales taxes.
What Happened: Armstrong's <a href="https://x.com/brian_armstrong/status/1858208662864429185">call</a>, shared in a series of tweets on Sunday, aligns with his broader vision for reducing government size and enhancing economic freedom.
&#8220;It's kind of crazy that we ask every adult in the U.S. to figure out how to pay their taxes,&#8221; Armstrong tweeted, pointing to the complexity of the current tax code, which spans an estimated 150,000 pages. 
He argued that offloading the tax reporting burden from millions of individual Americans to approximately 10,000 of the largest companies would simplify the system significantly.
Armstrong added, "Try to generate equivalent revenue via a sales tax, or on business income, etc."
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42010782/goldman-sachs-expands-bitcoin-etf-holdings-to-710-million">Goldman Sachs Expands Bitcoin ETF Holdings To $710 Million</a>
He also <a href="https://x.com/brian_armstrong/status/1858023954776207730">highlighted</a> United States Department of Government Efficiency&#8217;s unique potential to drive economic freedom in the U.S., describing it as a &#8220;once-in-a-lifetime opportunity.&#8221;
On Nov. 13, Trump officially named Musk and Ramaswamy as leaders of a newly established agency focused on optimizing federal operations through waste reduction, regulatory cuts, and agency restructuring.
He cited the need for systemic reforms, including a potential constitutional amendment capping government expenditure, to curtail what he sees as adverse incentives that expand government size over time. 
Armstrong proposed, "Every citizen then has skin in the game," suggesting a U.S. sovereign wealth fund that would provide citizens with shares and dividends from budget surpluses.
What&#8217;s Next: The debate is particularly timely as the industry prepares for events like Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19, where such disruptive ideas and technologies are set to take center stage.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42007247/bitcoin-dogecoin-success-driven-by-narrative-and-momentum-report-argues">Bitcoin, Dogecoin Success Driven By &#8216;Narrative And Momentum,&#8217; Report Argues</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Coinbase CEO Brian Armstrong Says DOGE Department Is A 'Once-In-A-Lifetime-Opprtunity,' Advocates Abolishing Individual Income Tax

SINT

SiNtx Technologies shares are trading higher after the company announced plans to buy back up to $500K worth of common stock in the upcoming quarters which can reduce the total shares outstanding by approximately 20%.

Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency
<ul>
<li>32 patients from the 100mg and 200mg cohorts, doses selected for the expansion phase, were characterized based on baseline biomarkers and analyzed for efficacy. Patients identified as insulin deficient (approx. 50% of the broader patient population) and insulin resistant were compared to examine the mean reduction in HbA1c at Week 26, following 4 weeks of dosing.</li>
<li>83%&nbsp;of patients with insulin deficiency responded to icovamenib, and showed a greater mean HbA1c reduction at Week 26 compared to baseline, than those that were found to be more insulin resistant (-1.23% vs -0.48%, placebo-adjusted, 22 weeks after last dose of icovamenib).</li>
<li>These two patient groups are pre-specified in the upcoming read out of the Phase IIb expansion portion of COVALENT-111 in December, reporting over 200 persons with type 2 diabetes (T2D) with 8 and 12 weeks of icovamenib treatment.</li>
</ul>

BMEA

Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction In HbA1c Greater Than 1% At Week 26 Following 4 Weeks Of Dosing In Type 2 Diabetes Patients Characterized By Insulin Deficiency

Morgan Stanley analyst Stephen Byrd maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Overweight and raises the price target from $20 to $28.

Morgan Stanley Maintains Overweight on Bloom Energy, Raises Price Target to $28

BTBT

Bit Digital shares are trading lower after the company reported worse-than-expected Q3 financial results.

MBX Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-Bariatric Hypoglycemia

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharmaceuticals shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $3 to $11.

ENPH

Enphase Energy Starts U.S. Shipments Of IQ Battery 5Ps, Enabling Projects To Qualify For Domestic Content Bonus Credit Under The Inflation Reduction Act

Morgan Stanley analyst Erik Woodring initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Equal-Weight rating and announces Price Target of $24.

Initiation

INGM

Morgan Stanley Initiates Coverage On Ingram Micro Holding with Equal-Weight Rating, Announces Price Target of $24

Windtree Therapeutics GAAP EPS of -$20.91 misses by $18.64

Windtree Therapeutics files to sell 27.67M shares of common stock for holders

An announcement from Windtree Therapeutics ( ($WINT) ) is now available. The Company has been actively engaging in financial maneuvers, including e...

Windtree Therapeutics Expands Stock and Restructures Finances

Windtree stock slides amid Phase 2b data for istaroxime for cardiogenic shock

Windtree Therapeutics ( ($WINT) ) has issued an update. Windtree Therapeutics, Inc. has updated its investor presentation materials as of October 1...

Windtree Therapeutics Updates Investor Presentation Materials

An update from Windtree Therapeutics ( ($WINT) ) is now available. Windtree Therapeutics, Inc. has promoted Jamie McAndrew to Senior Vice President...

Windtree Therapeutics Appoints New Senior VP and CFO

Windtree Therapeutics (WINT) announced the initiation of enrollment in the SEISMiC C trial in SCAI Stage C cardiogenic shock. This study follows th...

Windtree Therapeutics initiates SEISMiC C study of istaroxime

Windtree Therapeutics (WINT) announced the issuance of an istaroxime patent for Hong Kong. The patent is entitled, "Istaroxime-containing intraveno...

Windtree Therapeutics issued Hong Kong patent for istaroxime

Windtree Therapeutics (WINT) announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, afte...

Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed

Windtree Therapeutics appoints new CEO

WINT

Screenshot 2024-10-07 at 6.29.09 PM

Windtree Therapeutics (NASDAQ: WINT) Announces Positive Phase 2b Results For Istaroxime In Early Cardiogenic Shock Treatment

Press Releases

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

Windtree To Present at the ThinkEquity Conference on October 30th

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3

Comments

Windtree Therapeutics

Windtree Therapeutics (WINT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL